NGNE logo

NEUROGENE INC

NGNENASDAQ
πŸ† #2821 by market capUS Equity
$22.17β–Ό $0.68 (βˆ’2.96%)
Market closed Β· at close
πŸ””
Track NGNE
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.0%
7dβ–Ό 7.5%
14dβ–Ό 12.3%
30dβ–Ό 5.5%
ytdβ–² 6.7%
1yβ–² 10.1%
🏦Market Cap
$444M
Small Cap
πŸ“ˆRevenue Growth (YoY)
β€”
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
β€”
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$22.07 – $22.70
52-Week Range
$15.93 – $43.66
Volume (shares)
6,599
Avg Volume (shares)
β€”
Shares Outstanding
20.0M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
β€”
EPS (TTM)
$-3.16
Dividend Yield
β€”
Dilution (1yr)
+4.3%
NGNE logo

NEUROGENE INC

NGNE
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0β–Ό βˆ’100.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$103Mβ–² +24.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$78Mβ–² +9.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
15.5Mβ–² +4.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$93Mβ–Ό βˆ’$31M YoY
StockOtter Β· stockotter.space

About NEUROGENE INC

Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.